Making the case for cervical cancer prevention: what about equity?

Tsu, Vivien; Levin, Carol

doi:10.1016/s0968-8080(08)32411-2

Cited by 55 publications

(44 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well documented that HIV-infected women are at higher risk of HPV infection, with rates as high as 45–90% [11, 13, 57]. Not surprisingly, co-infection with multiple HPV subtypes, cytological abnormalities, and high-grade preinvasive lesions occur more frequently in these women.…”

Section: Discussionmentioning

confidence: 99%

“…Although standard treatment for premalignant cervical lesions appears effective, HIV-infected women are more likely to experience persistent or recurrent cervical dysplasia [37–39]. In resource-poor settings, the complex nature of Pap smear screening has resulted in several barriers to cervical cancer control [57, 58]. To overcome these barriers, visual techniques are being used increasingly in single-visit, see-and-treat programs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

Chibwesha

Cu‐Uvin

2011

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Cervical cancer remains the second commonest cancer among women worldwide, and more than 85% of the global burden of this disease occurs in the developing world. HIV-infected women have a higher likelihood of developing persistent high-risk human papillomavirus (HPV) infection, precancer, and invasive cervical cancer than seronegative women. Although highly effective primary and secondary prevention strategies are currently available, they remain inaccessible to the vast majority of women. Because of their simplicity and affordability, see- and-treat cervical cancer screening modalities have the potential to substantially improve women’s access to cancer prevention, as well as to create much needed infrastructure for future molecular-based cervical screening and HPV vaccination programs. Additional data addressing the effectiveness of see-and-treat approaches for HIV-infected women are urgently needed. Studies informing best practice guidelines on when to start, when to stop, and how frequently to screen HIV-infected women within the see-and-treat paradigm would be of great value.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

Chibwesha

Cu‐Uvin

2011

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

show abstract

“…2 Health education and advocacy have repeatedly been called for to tackle the barriers that prevent women from seeking health care in populations with rising socioeconomic inequalities, such as in the high Andean region of Latin America. 4,5 One recommendation for addressing the needs of fragmented populations calls for increased efforts to “bridge language, social, and cultural gaps between patients and oncology providers.” 6(p403) High-level recommendations for national cancer control plans (NCCPs) aim to bridge such gaps in equitable services.…”

Section: Introductionmentioning

confidence: 99%

Building a Network of Health Professionals for Breast and Cervical Cancer Control in the Andean Region

Mendoza-Cervantes

Otero

Zujewski

et al. 2018

JGO

View full text Add to dashboard Cite

PurposeCancer mortality is approximately twice as high in Latin American countries than in more developed countries. In particular, the countries of the high Andean region of Latin America carry a double burden of breast and cervical cancers. In these countries, there are disproportionately higher mortality to incidence ratios compared with other regions in Latin America. The US National Cancer Institute’s Center for Global Health, the Pan American Health Organization, and the Ministry of Health in Peru collaborated to design and execute an education and advocacy workshop in Lima, Peru. The workshop was convened to discuss regional challenges and practices, as well as to support the implementation of Plan Esperanza, Peru’s national cancer control plan.MethodsWorkshop participants included local and international experts to present the state of the science, health practitioners, and advocacy groups to discuss unique barriers that women in the region experience.ResultsInequalities in access to and distribution of medical expertise, lack of continuity of cancer control plans, and the need for sustained public buy-in emerged as obstacles.ConclusionThe workshop provided a forum to discuss key issues regarding breast and cervical cancer control among health professionals and advocates in Peru and the region. This article outlines the resulting recommendations.

show abstract

“…[9][10][11][12][13][14][15] Of additional concern is that most of the world's population does not have access to the equipment required to perform current HPV typing procedures. 16 Encouraging efforts have been made by PATH-QIAGEN to introduce screening assays to developing countries. 17 However, a robust typing assay still does not exist.…”

Section: Introductionmentioning

confidence: 99%

Robust hybridization-based genotyping probes for HPV 6, 11, 16 and 18 obtained via in vitro selection

Brukner

Larose²,

Gorska‐Flipot³

et al. 2010

J Nucleic Acids Invest

View full text Add to dashboard Cite

This paper describes the technical and analytical performance of a novel set of hybridization probes for the four GARDASIL® vaccine-relevant HPV types (6, 11, 16 and 18). These probes are obtained through in vitro selection from a pool of random oligonucleotides, rather than the traditional “rational design” approach typically used as the initial step in assay development. The type-specific segment of the HPV genome was amplified using a GP5+/6+ PCR protocol and 39 synthetic oligonucleotide templates derived from each of the HPV types, as PCR targets. The robust performance of the 4 selected hybridization probes was demonstrated by monitoring the preservation of the specificity and sensitivity of the typing assay over all 39 HPV types, using a different spectrum of HPV (genome equivalent: 103-109) and human DNA concentrations (10-100 ng) as well as temperature and buffer composition variations. To the Authors’ knowledge, this is a unique hybridization-based multiplex typing assay. It performs at ambient temperatures, does not require the strict temperature control of hybridization conditions, and is functional with a number of different non-denaturing buffers, thereby offering downstream compatibility with a variety of detection methods. Studies aimed at demonstrating clinical performance are needed to validate the applicability of this strategy

show abstract

Making the case for cervical cancer prevention: what about equity?

Cited by 55 publications

References 49 publications

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

Building a Network of Health Professionals for Breast and Cervical Cancer Control in the Andean Region

Robust hybridization-based genotyping probes for HPV 6, 11, 16 and 18 obtained via in vitro selection

Contact Info

Product

Resources

About